Paul Negulescu, Ph.D.

Dr. Negulescu is Vice President, Research, at Vertex Pharmaceuticals. He is responsible for leading the Vertex San Diego research site. Previously, he was Director of cell biology at Aurora Biosciences (acquired by Vertex). Under his leadership, Vertex San Diego has produced several novel drug candidates, including VX-770, a CFTR potentiator in Phase 3 clinical studies for the treatment of cystic fibrosis. He earned both a B.S. and Ph.D. in physiology from the University of California, Berkeley.